Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

748019

registered interest
date	04/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government how they ensure that, in responding to acid attacks, first responders are adequately equipped to deal with (1) the immediate effects, and (2) the need to prevent prolonged physical damage.
tabling member printed	Baroness Uddin
uin	HL473
answer	answer is ministerial correction date of answer 11/07/2017 answer text <p>Emergency medical technicians and paramedics operate to the Joint Royal Colleges Ambulance Liaison Committee Clinical Practise Guidelines 2016. This does not refer to the use of Diphoterine. Ambulance personnel would follow the chemical, biological, radiological and nuclear advice in the guidelines to disrobe the patient and decontaminate with water.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL475 question first answered 11/07/2017 15:01:51 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1827 label Biography information for Baroness Uddin

747416

registered interest
date	03/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government when they will publish their response to the Accelerated Access Review of innovative medicines and medical technologies.
tabling member printed	Lord Lansley
uin	HL380
answer	answer is ministerial correction date of answer 11/07/2017 answer text <p>In October 2016 the Accelerated Access Review set out a vision of faster patient access to 21st century medicines and medical technologies, making the United Kingdom a world leading place to design, develop and deploy medical innovations.</p><p> </p><p>The review made several recommendations to ensure that patients get new drugs and treatments faster while the National Health Service gets best value for money and remains at the forefront of innovation. The Government and its key delivery partners are reviewing the review’s recommendations and will respond in due course.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL381 HL383 question first answered 11/07/2017 13:59:51 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	123 label Biography information for Lord Lansley

747417

registered interest
date	03/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government whether they intend to establish the Accelerated Access Partnership as recommended in their Accelerated Access Review; and if so when.
tabling member printed	Lord Lansley
uin	HL381
answer	answer is ministerial correction date of answer 11/07/2017 answer text <p>In October 2016 the Accelerated Access Review set out a vision of faster patient access to 21st century medicines and medical technologies, making the United Kingdom a world leading place to design, develop and deploy medical innovations.</p><p> </p><p>The review made several recommendations to ensure that patients get new drugs and treatments faster while the National Health Service gets best value for money and remains at the forefront of innovation. The Government and its key delivery partners are reviewing the review’s recommendations and will respond in due course.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL380 HL383 question first answered 11/07/2017 13:59:51 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	123 label Biography information for Lord Lansley

747418

registered interest
date	03/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government whether a strategic commercial unit will be established within NHS England, as recommended in the Accelerated Access Review, and if so, when.
tabling member printed	Lord Lansley
uin	HL382
answer	answer is ministerial correction date of answer 11/07/2017 answer text <p>Consistent with recommendations set out in the Accelerated Access Review, NHS England continues to develop its commercial capacity and capability in relation to medicines procurement as well as the negotiation of bespoke commercial access arrangements for high cost drugs. As part of this, the Commercial Medicines Unit transferred across from the Department to NHS England on 1 April 2017. NHS England is currently in the process of recruiting to a number of other key posts to support the commercial function more broadly.</p> answering member printed Lord O'Shaughnessy question first answered 11/07/2017 14:30:38 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	123 label Biography information for Lord Lansley

747419

registered interest
date	03/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government what plans they have to introduce a "transformative designation", as proposed in the Accelerated Access Review, for the most strategically important products for the NHS.
tabling member printed	Lord Lansley
uin	HL383
answer	answer is ministerial correction date of answer 11/07/2017 answer text <p>In October 2016 the Accelerated Access Review set out a vision of faster patient access to 21st century medicines and medical technologies, making the United Kingdom a world leading place to design, develop and deploy medical innovations.</p><p> </p><p>The review made several recommendations to ensure that patients get new drugs and treatments faster while the National Health Service gets best value for money and remains at the forefront of innovation. The Government and its key delivery partners are reviewing the review’s recommendations and will respond in due course.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL380 HL381 question first answered 11/07/2017 13:59:51 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	123 label Biography information for Lord Lansley

746106

registered interest
date	28/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government how many mental health patients in England were sent away from their local area for treatment in each of the past three years for which figures are available.
tabling member printed	Lord Wigley
uin	HL248
answer	answer is ministerial correction date of answer 11/07/2017 answer text <p>The Out of Area Placement (OAP) definition was agreed in October 2016. The latest data published on OAPs covers the period from 17 October 2016 to 30 April 2017. During that time 4,153 OAPs have been recorded as starting in England.</p> answering member printed Lord O'Shaughnessy question first answered 11/07/2017 15:00:59 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	547 label Biography information for Lord Wigley

746107

registered interest
date	28/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government what steps they plan to take to address the shortage of psychiatrists.
tabling member printed	Lord Wigley
uin	HL249
answer	answer is ministerial correction date of answer 11/07/2017 answer text <p>A five year workforce plan to deliver the Five Year Forward View for Mental Health is currently being finalised by Health Education England (HEE) and will be published in due course. Analysis and development of the workforce strategy have been completed and HEE is now working with arm’s length body partners to agree the associated goals, trajectories, actions, and other deliverables associated with the implementation of the strategy.</p> answering member printed Lord O'Shaughnessy question first answered 11/07/2017 14:26:07 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	547 label Biography information for Lord Wigley

746109

registered interest
date	28/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Lumacaftor/ivacaftor: Children
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government whether they plan to allow the prescription of the drug Orkambi for cystic fibrosis sufferers under the age of 12; and if not, why not.
tabling member printed	Lord Wigley
uin	HL251
answer	answer is ministerial correction date of answer 11/07/2017 answer text <p>Orkambi does not have a marketing authorisation in the United Kingdom for use in the treatment of children aged under 12 with cystic fibrosis. Where clinically appropriate and subject to the relevant commissioner making funding available, Orkambi may be prescribed as an off-label drug. Off-label prescribing is supported in guidance given to prescribers by both the General Medical Council and by the Medicines and Healthcare products Regulatory Agency.</p> answering member printed Lord O'Shaughnessy question first answered 11/07/2017 15:01:27 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	547 label Biography information for Lord Wigley

732728

registered interest
date	26/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government when they intend to publish the next Tobacco Control Plan for England; and whether that plan will include recommendations for the NHS as well as for local government.
tabling member printed	Baroness Finlay of Llandaff
uin	HL166
answer	answer is ministerial correction date of answer 06/07/2017 answer text <p>The Government is developing a new tobacco control plan, which will be published shortly.</p> answering member printed Lord O'Shaughnessy question first answered 06/07/2017 15:54:14 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

732744

registered interest
date	26/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government, further to the Written Answer by the Parliamentary Under-Secretary of State, Department of Health, on 24 April (HC70973), when and how the Commission on Human Medicines "thoroughly review the data" on human papilloma virus (HPV) vaccine adverse reactions.
tabling member printed	The Countess of Mar
uin	HL182
answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>The Commission on Human Medicines (CHM) is the Government’s scientific advisory committee, from which the Medicines and Healthcare products Regulatory Agency (MHRA) seeks independent scientific advice.</p><p> </p><p>The CHM considered a thorough review of the safety of human papillomavirus (HPV) vaccine at its meeting on 16 July 2015. Prior to 2015, the CHM considered reviews of HPV vaccine at meetings in September 2012, September 2010, September 2009, June 2009 and February 2009. These reviews included evaluation of United Kingdom Yellow Card reports, analysis of data from the Clinical Practice Research Datalink (CPRD), published safety studies and safety data from other countries.</p><p>Most recently, the CHM considered the safety of HPV vaccine at its meeting on 15 October 2015. At this meeting, the MHRA sought advice from the CHM on the (Co)-Rapporteurs’ assessment reports prepared for the European Medicines Agency (EMA) review into reports of postural orthostatic tachycardia syndrome and complex regional pain syndrome following HPV vaccine, in order to inform the UK position in the review.</p><p><strong> </strong>As with all vaccines and medicines, the safety of HPV vaccine remains under continual review by the MHRA.</p> answering member printed Lord O'Shaughnessy question first answered 04/07/2017 16:04:46 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1861 label Biography information for The Countess of Mar